Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 7/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694725 | 0.82 | AURKA (0.45) | DRD4HTR1AAURKAKDRAURKB | |
| SCHEMBL6702960 | 0.78 | MAPK8 (0.48) | PARP2PARP1JAK1JAK2 | |
| SCHEMBL6694944 | 0.76 | DRD2 (0.57) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL6695929 | 0.75 | JAK2 (0.49) | DRD2CXCR3HTR1AJAK1JAK2 | |
| SCHEMBL6700023 | 0.73 | CHRNB2 (0.37) | PARP1 | |
| SCHEMBL6701277 | 0.72 | DRD2 (0.66) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL3968181 | 0.69 | DRD2 (0.73) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL27563358 | 0.69 | — | — | |
| SCHEMBL6699529 | 0.69 | TBK1 (0.44) | PARP1 | |
| SCHEMBL27455010 | 0.67 | DRD4 (0.75) | DRD2DRD4DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | claimed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | APOB, APOL1, TTR | DRD2 3054/4885DRD4 3005/4885DRD3 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.